Will monoclonal antibodies to CGRP become the first line treatment for migraine or episodic cluster headache?

Prof. Lars Edvinsson of Lund University Hospital, Sweden, explains that he believes calcitonin gene-related peptide (CGRP)-blocking drugs will become first-line agents in the treatment of both migraine and cluster headache in the future. Prof. Edvinsson also recognizes that we have a long way to go before we fully understand the mechanisms underlying these two very different types of headaches.